Gubra Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Gubra has a total shareholder equity of DKK463.9M and total debt of DKK0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are DKK610.8M and DKK146.9M respectively.

Belangrijke informatie

Verhouding schuld/eigen vermogen

DKK 0

Schuld

Rente dekkingsratio	n/a
Contant	DKK 446.89m
Aandelen	DKK 463.88m
Totaal verplichtingen	DKK 146.88m
Totaal activa	DKK 610.76m

Recente financiële gezondheidsupdates

Geen updates

Recent updates

Analyse van de financiële positie

Kortlopende schulden: PI3's short term assets (DKK492.3M) exceed its short term liabilities (DKK68.0M).

Langlopende schulden: PI3's short term assets (DKK492.3M) exceed its long term liabilities (DKK78.9M).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: PI3 is debt free.

Schuld verminderen: PI3 had no debt 5 years ago.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: PI3 has sufficient cash runway for more than 3 years based on its current free cash flow.

Voorspelling contante baan: PI3 has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 76.5% each year

Gubra Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Recent updates

First half 2024 earnings released: kr.1.20 loss per share (vs kr.1.30 loss in 1H 2023)

New major risk - Financial position

Chief Executive Officer recently sold €4.1m worth of stock

Boehringer Ingelheim and Gubra Announce Start of Clinical Development of A Potential First-In-Class, Triple Agonist, Obesity Treatment

Full year 2023 earnings released: kr.2.94 loss per share (vs kr.0.37 profit in FY 2022)

Gubra A/S to Report First Half, 2024 Results on Aug 23, 2024

New minor risk - Share price stability

High number of new and inexperienced directors

Gubra A/S Announces First Subject Dosed in Phase 1 Clinical Trial of Amylin Agonist (GUBamy) for the Treatment of Obesity

Gubra A/S Announces Board Appointments

Gubra A/S Submits Clinical Trial Application (CTA) for First-In-Human Amylin Trial

First half 2023 earnings released

Gubra A/S (CPSE:GUBRA) acquired Minigut Aps.

Gubra A/S Announces Updates to Its Pipeline

Gubra A/S and Boehringer Ingelheim Share Phase 1 Results for BI 1820237

Gubra A/S Provides Revenue Guidance for the Year 2023

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Analyse van de cashflow

Ontdek gezonde bedrijven